The Role of Expression of Lymphoid Enhancer-Binding Factor-1 (LEF-1) in Patients with Chronic Lymphocytic Leukemia | ||||
| The Medical Journal of Cairo University | ||||
| Article 97, Volume 86, September, September 2018, Page 2931-2937 PDF (412.02 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/mjcu.2018.59718 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| GHADA AHMED EL-KHAMESSY, M.Sc.; JEHAN ABDEL-HAMED EL-SHARNOUBY, M.D.; ENAAM SALAH ABD EL-BAR, M.D.; TAMER ABD EL-HAMID ELBEDEWY, M.D. | ||||
| The Departments of Clinical Pathology* and Internal Medicine**, Faculty of Medicine, Tanta University | ||||
| Abstract | ||||
| Abstract Background: Lymphoid Enhancer-Binding factor-1 (LEF-1) is a 48-kD nuclear protein that is expressed in pro-B cells and mature T cells but not in mature B cell. LEF-1 binds to a functionally important site in the T-cell receptor alpha (TCR.t) enhancer and confers maximal enhancer activity; LEF-1 belongs to a family of regulatory proteins that share homology with high mobility group protein-1 (HMG1). Lymphoid Enhancer-Binding factor-1 LEF-1 is sufficient to differentiate CLL/SLL from other small B-cell lymphomas and may serve as a useful tool in the diagnosis of CLL/SLL, LEF-1 is highly associated with CLL/SLL among small B-cell lymphomas and therefore can serve as a useful immune-histo-chemistry (IHC) marker for diagnosis and differential diagnosis of CLL/SLL. Aim of the Study: Our aim is to evaluate the role of Lymphoid Enhancer-Binding factor-1 (LEF-1) expression by flow cytometry in patients with chronic lymphocytic leukemia. Methods and Material: This study was carried out on 45 newly diagnosed B-CLL patients attending the hematology oncology clinic of Tanta University Hospitals. The patients were selected for the study on the basis of standard clinical, hematological and immune phenotypic criteria for diagnosis of CLL, In addition to 15 apparently healthy subjects serving as healthy control group. Subjects included in this study were classified into the following groups: Chronic Lymphocytic Leukemia Group I: Included 45 patients with chronic lymphocytic leukemia. Group I: Healthy Control Group. This group included 15 apparently healthy subjects. Results: There was no significant correlation between LEF-1 expression and age and sex, there was a significant negative correlation between LEF1 expression and Hb and platelet count, there was a significant positive correlation between LEF-1 expression and TLC, ALC and LDH, According to LEF1 expression, there was 100% of patients positively expressed LEF-1 and negative in control cases and there was significant positive correlation between LEF-1 expression and Zap 70 expression. Conclusions: LEF-1expression on CLL cells represent an important adverse diagnostic marker and therefore its expres-sion should be routinely investigated for a better diagnostic and prognostic assessment of CLL patients and showed be taken in consideration in designing further therapeutic strategies based on patient-specific risk factors. | ||||
| Keywords | ||||
| Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) – Flow cytometry – LEF1 | ||||
|
Statistics Article View: 196 PDF Download: 176 |
||||
